S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:OMCL

Omnicell Stock Forecast, Price & News

$177.22
-2.56 (-1.42%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$176.12
$179.70
50-Day Range
$148.43
$183.62
52-Week Range
$101.94
$187.29
Volume
202,700 shs
Average Volume
296,296 shs
Market Capitalization
$7.79 billion
P/E Ratio
103.64
Dividend Yield
N/A
Beta
1.06
30 days | 90 days | 365 days | Advanced Chart
Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.


Omnicell logo

About Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.

Headlines

Troy Hilsenroth Appointed CEO of biolog-id - Business Wire
November 24, 2021 |  businesswire.com
Troy Hilsenroth Appointed CEO of biolog-id - Yahoo Finance
November 24, 2021 |  finance.yahoo.com
Omnicell (NASDAQ:OMCL) Sets New 1-Year High at $186.73
November 22, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Electronic computers
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
2,860
Year Founded
1992

Sales & Book Value

Annual Sales
$892.21 million
Cash Flow
$3.61 per share
Book Value
$25.29 per share

Profitability

Net Income
$32.19 million
Pretax Margin
6.83%

Debt

Price-To-Earnings

Miscellaneous

Free Float
42,787,000
Market Cap
$7.79 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/07/2022

Social Links


MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

1065th out of 1,391 stocks

Electronic Computers Industry

6th out of 11 stocks

Analyst Opinion: 1.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Omnicell (NASDAQ:OMCL) Frequently Asked Questions

Is Omnicell a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Omnicell stock.
View analyst ratings for Omnicell
or view top-rated stocks.

How has Omnicell's stock price been impacted by Coronavirus (COVID-19)?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OMCL shares have increased by 128.9% and is now trading at $177.22.
View which stocks have been most impacted by COVID-19
.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Monday, February 7th 2022.
View our earnings forecast for Omnicell
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported $1.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.63 by $0.45. The firm had revenue of $296.40 million for the quarter, compared to the consensus estimate of $283.82 million. Omnicell had a net margin of 7.50% and a trailing twelve-month return on equity of 12.51%. During the same quarter in the prior year, the firm earned $0.40 earnings per share.
View Omnicell's earnings history
.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of $3.800-$3.850 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.730. The company issued revenue guidance of $1.13 billion-$1.13 billion, compared to the consensus revenue estimate of $1.11 billion.

What price target have analysts set for OMCL?

7 brokers have issued 1 year price objectives for Omnicell's shares. Their forecasts range from $95.00 to $211.00. On average, they expect Omnicell's share price to reach $169.50 in the next year. This suggests that the stock has a possible downside of 4.4%.
View analysts' price targets for Omnicell
or view top-rated stocks among Wall Street analysts.

Who are Omnicell's key executives?

Omnicell's management team includes the following people:
  • Randall A. Lipps, Chairman, President & Chief Executive Officer
  • Randy Lipps, Chairman, President, CEO & Founder
  • Bill Wingfield, Vice President-North America Service & Operations
  • Peter J. Kuipers, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
  • Giri Chodavarapu, Chief Information Officer

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell CEO Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among Omnicell's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (5.62%), Conestoga Capital Advisors LLC (3.46%), Macquarie Group Ltd. (2.57%), Neuberger Berman Group LLC (2.38%), Dimensional Fund Advisors LP (1.98%) and Geneva Capital Management LLC (2.00%). Company insiders that own Omnicell stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell
.

Which major investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, ArrowMark Colorado Holdings LLC, Voloridge Investment Management LLC, Tributary Capital Management LLC, Dimensional Fund Advisors LP, Peregrine Capital Management LLC, West Coast Financial LLC, and Thrivent Financial for Lutherans. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, James T Judson, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim, and Scott Peter Seidelmann.
View insider buying and selling activity for Omnicell
or view top insider-selling stocks.

Which major investors are buying Omnicell stock?

OMCL stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Voya Investment Management LLC, Principal Financial Group Inc., Barclays PLC, Victory Capital Management Inc., Nordea Investment Management AB, CastleArk Alternatives LLC, and Ziegler Capital Management LLC.
View insider buying and selling activity for Omnicell
or or view top insider-buying stocks.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $177.22.

How much money does Omnicell make?

Omnicell has a market capitalization of $7.79 billion and generates $892.21 million in revenue each year. The company earns $32.19 million in net income (profit) each year or $1.71 on an earnings per share basis.

How many employees does Omnicell have?

Omnicell employs 2,860 workers across the globe.

Does Omnicell have any subsidiaries?

The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.

When was Omnicell founded?

Omnicell was founded in 1992.

What is Omnicell's official website?

The official website for Omnicell is www.omnicell.com.

Where are Omnicell's headquarters?

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at (650) 251-6100, via email at [email protected], or via fax at 847-596-3402.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.